Skip to main content

Your search for “Sanford Stem Cell Clinical Center” returned 103 results

Body’s Own Gene Editing System Generates Leukemia Stem Cells

June 9, 2016

Cancer stem cells are like zombies — even after a tumor is destroyed, they can keep coming back. These cells have an unlimited capacity to regenerate themselves, making more cancer stem cells and more tumors. Researchers at University of California San Diego School of Medicine have now unraveled how pre-leukemic…

An Errant Editing Enzyme Promotes Tumor Suppressor Loss and Leukemia Propagation

January 3, 2019

UC San Diego researchers have found a stem cell enzyme copy edits more than 20 tumor types, providing new therapeutic target for preventing cancer cell resistance to chemotherapy and radiation.

Clinical Trial To Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

September 9, 2014

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.

UC San Diego and GSK Collaborate to Eradicate Cancer Stem Cells, Treat Leukemia

July 8, 2015

…Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK’s Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams. Catriona Jamieson, MD, PhD, associate…

Phase I Trial Finds Experimental Drug Safe in Treating Chronic Lymphocytic Leukemia

June 1, 2018

…a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells — their ability to self-renew and resist terminal differentiation and senescence.

UC San Diego Researchers Launch Combination Drug Trial to Eradicate B-Cell Malignancies

March 9, 2018

…grant from the state’s stem cell agency, researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target…

Putting ‘Super’ in Natural Killer Cells

June 11, 2020

Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells — a type of immune cell — with measurably stronger activity against a form of leukemia, both in vivo and in vitro.

CIRM Approves $5.8 Million Grant for CAR-T Therapy that Targets Cancer Stem Cells

July 20, 2017

…researchers to develop a new immunotherapy in which patients’ cells would be equipped with a special receptor that recognizes and targets cancer stem cells, whose survival abilities often render standard therapies ineffective or short-term.

UC San Diego Health among First in Nation to Perform Regenerative Brain Cell Procedure for Epilepsy

July 26, 2023

UC San Diego Health is among the first in the nation to perform an experimental regenerative brain cell therapy for epilepsy aimed at eliminating seizures.

Two Anti-viral Enzymes Transform Pre-Leukemia Stem Cells into Leukemia

January 26, 2021

Viral infections and space travel similarly trigger inflammation and the enzymes APOBEC3C and ADAR1; UC San Diego researchers are developing ways to inhibit them as a means to potentially lower cancer risk for both astronauts and people on Earth.

Category navigation with Social links